First AD

Second AD

Neal Shore, MD, FACS, is the medical director for the Carolina Urologic Research Center

Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancercomes and Preserving Patient Quality of Life

Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

Prostate Cancer

JAN-22-OSD1189 - /clinical/prostate-cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Insights Video Series

Advancements in Targeting the Androgen Receptor Pathway in Prostate Cancer

OncLive Insights

GU medical oncologist Dr. Rana McKay and urologist Dr. Neal Shore explore how predictive biomarkers and genetic testing are informing risk assessment and guiding personalized treatment decisions in clinical practice